scholarly journals Noninvasive ductal carcinoma of the male breast with marked apocrine metaplasia.

1994 ◽  
Vol 33 (4) ◽  
pp. 691-696 ◽  
Author(s):  
Mituyuki KINJO ◽  
Keiko TAIRA ◽  
Akira TERUYA ◽  
Cyorei YOHENA ◽  
Haruo KINA ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Male Breast ◽  
Apocrine Metaplasia ◽  
Noninvasive Ductal Carcinoma

scholarly journals A CASE OF NONINVASIVE DUCTAL CARCINOMA WITH APOCRINE METAPLASIA

1998 ◽  
Vol 59 (8) ◽  
pp. 2005-2008 ◽  
Author(s):  
Noriaki WADA ◽  
Masato FUJISAKI ◽  
Masaru KOJIMA ◽  
Takayuki TAKAHASHI ◽  
Shinobu HIRAHATA ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Apocrine Metaplasia ◽  
Noninvasive Ductal Carcinoma

Synchronous bilateral noninvasive ductal carcinoma of the male breast: A case report

Breast Cancer ◽  
2003 ◽  
Vol 10 (2) ◽  
pp. 163-166 ◽  
Author(s):  
Kenzo Okada ◽  
Shinsuke Kajiwara ◽  
Hitoshi Tanaka ◽  
Goi Sakamoto
Keyword(s):  
Case Report ◽  
Ductal Carcinoma ◽  
Male Breast ◽  
Noninvasive Ductal Carcinoma

scholarly journals Noninvasive ductal carcinoma with marked apocrine metaplasia.

1987 ◽  
Vol 26 (6) ◽  
pp. 1093-1098 ◽  
Author(s):  
Toshiki HIROSE ◽  
Tsunehiro NISHI ◽  
Yoko KOKAI ◽  
Harumi YAMAMURA ◽  
Miharu TSUCHIYA ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Apocrine Metaplasia ◽  
Noninvasive Ductal Carcinoma

Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival

2000 ◽  
Vol 18 (16) ◽  
pp. 2948-2956 ◽  
Author(s):  
Achille Pich ◽  
Elena Margaria ◽  
Luigi Chiusa
Keyword(s):  
Breast Carcinoma ◽  
Prognostic Value ◽  
Ductal Carcinoma ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Male Breast ◽  
Male Breast Carcinoma ◽  
P53 Immunoreactivity ◽  
Mib 1

PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC). PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal carcinoma were retrospectively studied. All patients received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins were immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, and bcl-2 124 monoclonal antibodies (mAbs). Estrogen, progesterone, and androgen receptors were detected using specific mAbs. Cell proliferation was assessed by MIB-1 mAb. RESULTS: In univariate analysis, c-myc, c-erbB-2, and p53 protein overexpression was significantly correlated with prognosis. The median survival was 107 months for c-myc–negative and 52 months for c-myc–positive patients (P = .01), 96 months for c-erbB-2–negative and 39 months for c-erbB-2–positive patients (P = .02), and 100 months for p53-negative and 33 months for p53-positive patients (P = .0008). Tumor histologic grade (P = .01), tumor size (P = .02), patient age at diagnosis (P = .03), and MIB-1 scores (P = .0004) also had prognostic value. In multivariate analysis, only c-erbB-2 and p53 immunoreactivity retained independent prognostic significance. All nine patients who did not express c-erbB-2 and p53 proteins were alive after 58 months, whereas none of the 14 patients expressing both proteins survived at 61 months follow-up (P = .0002). CONCLUSION: Overexpression of c-myc, c-erbB-2, and p53 proteins may be regarded as an additional prognostic factor in MBC. The combination of c-erbB-2 and p53 immunoreactivity can stratify patients into different risk groups.

scholarly journals Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity

2020 ◽  
Vol 16 (1) ◽  
pp. 77-80
Author(s):  
Saida Sakhri ◽  
◽  
Olfa Jaidane ◽  
Malek Bouhani ◽  
Olfa Adouni ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Male Breast ◽  
Rare Entity

Ductal carcinoma in situ of the male breast. Analysis of 31 cases

1997 ◽  
Vol 33 (1) ◽  
pp. 35-38 ◽  
Author(s):  
B. Cutuli ◽  
J.M. Dilhuydy ◽  
B. De Lafontan ◽  
J. Berlie ◽  
M. Lacroze ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Male Breast

Male Breast Cancer: 13-Year Single Institution Experience

2020 ◽  
Vol 86 (10) ◽  
pp. 1345-1350
Author(s):  
Marissa K. Srour ◽  
Farin Amersi ◽  
James Mirocha ◽  
Armando E. Giuliano ◽  
Alice Chung
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Recurrence Score ◽  
Breast Conserving Surgery ◽  
Male Breast ◽  
Brca Mutations ◽  
Estrogen Receptor Positive ◽  
Stage 1

Due to the low incidence of male breast cancer (BC), there are few studies evaluating outcomes. We evaluated the clinicopathologic features and outcomes of male BC. Male patients with BC from January 2006 to December 2018 were identified. Of 49 patients, mean age was 64 (range 33-94) years. Of the 27 (55.1%) patients who had genetic testing, 9 (33.3%) had a Breast Cancer gene (BRCA) 1 or 2 mutation. The majority of patients had a mastectomy (n = 43/49, 87.8%) and had invasive ductal carcinoma (n = 47/49, 95.9%). 20 patients (n = 20/43, 46.5%) had positive lymph nodes. 41 (n = 41/47, 87.2%) patients had estrogen receptor positive disease. The majority of patients were pathologic stage 2 (n = 21/46, 45.7%), followed by stage 1 (n = 15/46, 32.6%), stage 3 (n = 6/46, 13.0%), and stage 4 (n = 4/46, 8.7%). Eight patients had the 21-gene recurrence score performed. Of patients with stage 1-3 BC, 10 (n = 10/43, 23.3%) patients had recurrence. With median follow-up of 4.1 (range .6-10.6) years, 5-year overall survival was 82.9% and 5-year disease-free survival was 65.9%. In conclusion, our cohort of patients with male BC had a high incidence of BRCA mutations and most commonly had high-grade estrogen positive stage 2 tumors. Breast conserving surgery was utilized in 4% of patients and genomic testing utilized in 55% of patients.

Sign in / Sign up

Export Citation Format

Share Document